Insights into Pregabalin and Etoricoxib Combination Therapy for **Neuropathic Pain**

Table of Content

INTRODUCTION

Neuropathic pain is a complex and chronic condition caused by lesions or dysfunction in the somatosensory nervous system. Unlike nociceptive pain, which results from tissue injury, neuropathic pain arises from abnormal neural activity, leading to sensations such as burning, tingling, or sharp, shooting pain. It significantly impairs patients' quality of life by causing persistent discomfort, emotional distress, and functional limitations. Globally, neuropathic pain is estimated to affect 7-10% of the population, with a higher prevalence in individuals with underlying conditions such as diabetes, postherpetic neuralgia, or spinal cord injuries (1). This widespread burden results in considerable personal, societal, and healthcare-related costs.

Current treatments for neuropathic pain include anticonvulsants, antidepressants, and opioids, which aim to alleviate symptoms and improve functionality. However, monotherapy often proves insufficient for many patients, with partial or no response reported in a significant proportion. Inadequate relief from traditional single-agent therapies underscores the need for alternative approaches that address the multifactorial nature of neuropathic pain (2).

Combination therapy has emerged as a promising strategy to enhance treatment efficacy and tolerability. Pregabalin, an alpha-2-delta ligand, is a cornerstone in neuropathic pain management. It reduces calcium influx into hyperexcited neurons, modulating the release of excitatory neurotransmitters such as glutamate and substance P. These mechanisms decrease neuronal hyperexcitability and central sensitization, making pregabalin effective in conditions such as diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia (3).

Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, complements this action by addressing the inflammatory components of pain. Prostaglandins, which are synthesized via the COX-2 enzyme, contribute to central and peripheral

sensitization, exacerbating chronic pain. Etoricoxib's ability to selectively inhibit COX-2 reduces prostaglandin production, providing potent analgesic and anti-inflammatory effects. Its efficacy in managing both inflammatory and nociceptive pain conditions has been well-documented (4).

The combination of pregabalin and etoricoxib offers a synergistic approach, targeting both neuropathic and nociceptive components of pain. Pregabalin's modulation of hyperexcited neurons addresses central sensitization, while etoricoxib mitigates peripheral inflammatory processes. Together, this combination holds promise for enhancing pain relief, reducing symptom severity, and improving patient-reported outcomes. However, the real-world utility, safety, and acceptability of this regimen remain underexplored. This study seeks to bridge this knowledge gap, evaluating the clinical benefits and limitations of pregabalin and etoricoxib combination therapy in diverse patient populations.

Limitations of Current Treatments

The management of neuropathic pain poses significant challenges due to its heterogeneous etiology and pathophysiology. Existing pharmacological options, including selective serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and tricyclic antidepressants, are often associated with suboptimal efficacy, delayed onset of action, and undesirable side effects. Studies reveal that only 40-60% of patients achieve meaningful pain relief with these treatments, with many experiencing residual pain that affects daily functioning (5). Side effects such as sedation, dizziness, gastrointestinal disturbances, and weight gain further complicate adherence, leading to discontinuation in a significant proportion of cases (6).

Moreover, monotherapy often fails to address the multifaceted nature of neuropathic pain, which involves both peripheral and central sensitization. For instance, pregabalin's primary mechanism targets neuronal hyperexcitability, but

it does not directly influence inflammatory processes that may contribute to pain persistence. Similarly, etoricoxib's anti-inflammatory effects do not address the central mechanisms driving chronic neuropathic pain. These limitations highlight the need for combination therapies that can simultaneously target multiple pathways involved in pain perception and modulation (7).

The pregabalin and etoricoxib combination offers a dual approach, addressing the shortcomings of existing therapies. By combining the central effects of pregabalin with the peripheral anti-inflammatory actions of etoricoxib, this regimen has the potential to provide more comprehensive pain relief and improve overall treatment outcomes. However, further investigation is needed to determine its optimal dosing, safety profile, and long-term efficacy in real-world clinical settings.

RATIONALE OF THE STUDY

The heterogeneity of neuropathic pain and the limitations of current treatment options necessitate innovative approaches to improve patient outcomes. The pregabalin and etoricoxib combination represents a promising therapeutic strategy, leveraging complementary mechanisms to address the complex pathophysiology of neuropathic pain. Pregabalin's ability to modulate neuronal hyperactivity and reduce central sensitization, combined with etoricoxib's potent anti-inflammatory and analgesic effects, offers a synergistic approach to pain management.

Despite encouraging preliminary evidence, the clinical adoption of this combination remains limited due to gaps in understanding its real-world application. Variations in patient demographics, comorbidities, and treatment histories can significantly influence therapeutic outcomes. Additionally, concerns regarding potential side effects, such as gastrointestinal discomfort from COX-2

inhibitors or dizziness from pregabalin, warrant careful evaluation. This study aims to address these gaps, providing actionable insights to guide clinicians in optimizing the use of this combination for neuropathic pain.

STUDY OBJECTIVE

The primary objective of this study is to evaluate the clinical utility of pregabalin and etoricoxib combination therapy in managing neuropathic pain. Specifically, the study seeks to:

1. **Assess Clinician Awareness and Familiarity:** Evaluate healthcare professionals' understanding of the combination's pharmacological mechanisms and therapeutic potential.
2. **Evaluate Prescribing Patterns:** Analyze how frequently and under what circumstances this combination therapy is prescribed compared to other treatments.
3. **Analyze Effectiveness and Safety:** Assess clinicians' perceptions of the combination's efficacy in alleviating neuropathic pain and its associated safety profile.
4. **Explore Patient Demographics:** Identify patient populations most commonly treated with this combination, including those with comorbid conditions.
5. **Identify Barriers and Opportunities:** Investigate challenges to the adoption of this combination therapy and explore strategies for enhancing its utilization.

METHODS

1. **Survey Design** A structured questionnaire was developed to capture key aspects of pregabalin and etoricoxib combination therapy, including:
    - Clinician familiarity with the combination therapy's pharmacological basis.
    - Prescribing patterns and clinical decision-making factors.
    - Perceived effectiveness and safety in managing neuropathic pain.
    - Demographics of patients receiving the therapy.
    - Barriers and facilitators in clinical practice. The questionnaire was reviewed by experts in pain management and pharmacology to ensure validity and relevance.

2. **Participant Recruitment** The survey targeted neurologists, pain specialists, general practitioners, and other healthcare professionals involved in neuropathic pain management. Participants were selected from various geographic regions to ensure diverse representation.

3. **Data Collection** Data were collected over three months using electronic and physical survey methods. Participant anonymity was maintained to encourage honest responses. The survey included closed-ended questions for quantitative analysis and open-ended questions for qualitative insights.

4. **Data Analysis** Quantitative data were analyzed using descriptive and inferential statistical methods to summarize prescribing trends, effectiveness ratings, and reported side effects. Comparative analyses were conducted based on clinician specialties, patient demographics, and treatment settings. Qualitative responses were thematically analyzed to identify patterns and unique perspectives.

5. **Ethical Considerations** Ethical guidelines for human research were strictly followed. Participants provided informed consent, and confidentiality was maintained throughout the study.

RESULTS

A total of 73 HCPs participated in the survey. Below is the summary of the responses.

1. **In your clinical practice, how frequently do you prescribe pregabalin in combination with COX inhibitors?**

   A. Frequently

   B. Occasionally

   C. Rarely

   D. Never



- In clinical practice, 51% of clinicians frequently prescribe pregabalin with COX inhibitors to manage pain and inflammation. Another 33% occasionally use this combination, typically in cases where inflammation is present alongside pain. A smaller group, 16%, rarely prescribes these medications together. Interestingly, no clinicians reported never using pregabalin with COX inhibitors, suggesting some level of familiarity with this approach in their practice.

2. According to your opinion, in which type of neuropathic pain do you generally prefer to prescribe Pregabalin and Etoricoxib combination?

A. Diabetic peripheral neuropathic pain

B. Chronic low back pain/ Sciatica

C. Post herpetic neuralgia

D. Trigeminal Neuralgia

E. All of the above



- 33% of clinicians prefer prescribing Pregabalin and Etoricoxib for chronic low back pain or sciatica, while 26% use it for post herpetic neuralgia. About 25% opt for this combination in diabetic peripheral neuropathic pain, and 8% prefer it for trigeminal neuralgia.
- A small group (8%) believes it can be effective for all these neuropathic pain conditions.

3. **According to your opinion, what would be the typical duration of treatment with the combination of Pregabalin and Etoricoxib for chronic low back pain?**

A. <6 months

B. 6 – 12 months

C. > 1 year



- The typical duration of treatment with the combination of Pregabalin and Etoricoxib for chronic low back pain varies among clinicians. Nearly half (49%) believe the treatment lasts for less than six months, suggesting short-term relief. About 25% think it may be prescribed for six to twelve months when longer pain management is needed.
- Meanwhile, 26% of clinicians believe the combination could be used for more than one year in cases that require extended treatment. This reflects the different clinical approaches to managing chronic low back pain.

4. According to your opinion, what is the recommended starting dose of Pregabalin and Etoricoxib fixed dose combination in neuropathic pain?

A. Pregabalin 75 mg/ Etoricoxib 60 mg

B. Pregabalin 150 mg/ Etoricoxib 90 mg

C. Pregabalin 75 mg/ Etoricoxib 90 mg

D. Pregabalin 75 mg/ Etoricoxib 60 mg



- The recommended starting dose of the Pregabalin and Etoricoxib fixed-dose combination for neuropathic pain varies among clinicians. The majority (49%) suggest starting with Pregabalin 75 mg/ Etoricoxib 60 mg. Another 18% prefer Pregabalin 150 mg/ Etoricoxib 90 mg as the initial dose.
- Some clinicians (16%) recommend Pregabalin 75 mg/ Etoricoxib 90 mg, while another 16% believe Pregabalin 75 mg/ Etoricoxib 60 mg is sufficient to start treatment. This highlights the diverse clinical approaches to initiating therapy for neuropathic pain.

5. In your clinical practice, which patient population would be benefitted the most from Pregabalin and Etoricoxib combination therapy for neuropathic pain?

A. Young adults

B. Paediatric patients

C. Elderly patients



- In clinical practice, 41% of clinicians believe young adults benefit the most from the combination therapy of Pregabalin and Etoricoxib for neuropathic pain.
- 34% think paediatric patients are the primary beneficiaries, while 25% believe elderly patients would gain the most from this treatment. This reflects the varied opinions based on patient age groups.

6. In your clinical practice, how would you recommend the dosage regimen for Pregabalin and Etoricoxib combination for treatment of neuropathic pain?

A. Once daily

B. Twice daily

C. As in when needed



- In clinical practice, the majority of clinicians (59%) recommend taking the combination of Pregabalin and Etoricoxib once daily for the treatment of neuropathic pain, emphasizing convenience and sustained effectiveness. 16% prefer a twice-daily regimen, which may be necessary for patients with more frequent pain relief needs.
- A smaller group, 25%, believes the dosage should be taken as needed, depending on the individual's pain level and response. This shows varying approaches to prescribing the medication based on patient circumstances.

7. Do you believe that Pregabalin and Etoricoxib combination therapy is superior to Pregabalin monotherapy for pain management?

A. Yes

B. No



- **Yes (59%)**: Clinicians who select this option believe that Pregabalin and Etoricoxib combination therapy is superior to Pregabalin monotherapy for pain management, likely due to the added anti-inflammatory benefit provided by Etoricoxib.
- **No (41%)**: This group does not believe that the combination therapy is more effective than Pregabalin alone, possibly preferring the simplicity and established efficacy of monotherapy.

8. According to your opinion, what would be the typical duration for the Pregabalin and Etoricoxib combination to show full therapeutic effect?

A. Within 30 minutes

B. Within 30 – 60 minutes

C. Within 1 - 2 hours

D. Within 2 - 6 hours



- Most clinicians (51%) believe that Pregabalin and Etoricoxib combination shows its full therapeutic effect within 30 minutes of administration, reflecting its fast onset of action.
- 17% think it takes 30 to 60 minutes to reach full effect, while another 16% believe it takes 1 to 2 hours. A smaller group (16%) believes the combination may take 2 to 6 hours to show the full therapeutic impact.
- This highlights the varied expectations for the onset of action in clinical practice.

9. **In your clinical practice, have you found it necessary to discontinue the combination of Pregabalin and Etoricoxib due to adverse effects?**

A. Yes

B. No



- Yes (66%): Clinicians who select this option have found it necessary to discontinue the combination of Pregabalin and Etoricoxib due to adverse effects in some of their patients.
- No (34%): This group has not found it necessary to discontinue the combination therapy, suggesting better tolerability in their patient population.
- This survey highlights varying experiences with the safety and tolerability of Pregabalin and Etoricoxib combination therapy in clinical practice.

10. In your clinical practice, what would be your strategy if Pregabalin and Etoricoxib combination does not provide sufficient pain relief?

A. Switch to an alternative therapy

B. Addition of another drug for pain reduction

C. Increase in pregabalin dose



- In clinical practice, the majority of clinicians (49%) would switch to an alternative therapy if the combination of Pregabalin and Etoricoxib does not provide sufficient pain relief.
- About 25% would add another drug to enhance pain control, while 26% might consider increasing the dose of Pregabalin.
- These responses reflect the various approaches clinicians take when the initial combination therapy proves ineffective.

11. According to your opinion, which adverse effect is commonly associated with long-term use of Pregabalin and Etoricoxib combination therapy?

A. Weight gain

B. Hypotension

C. Respiratory depression

D. Photosensitivity



- The most commonly associated adverse effect with long-term use of Pregabalin and Etoricoxib combination therapy, as perceived by clinicians, is weight gain (51%). Another notable adverse effect is hypotension, cited by 25% of respondents.
- Some clinicians also identified photosensitivity (16%) and respiratory depression (8%) as potential concerns with prolonged use.
- This reflects the variety of side effects that practitioners observe with long-term therapy.

12. In your clinical practice, what degree of reduction in visual analogue scale (VAS) have you observed with the Pregabalin and Etoricoxib combination in patients suffering from neuropathic pain?

A. <25%

B. 25-50%

C. 50-75%

D. >75%



- Most clinicians (41%) have observed a less than 25% reduction in Visual Analogue Scale (VAS) scores in patients suffering from neuropathic pain when using Pregabalin and Etoricoxib combination therapy. Eighteen percent have seen a 25-50% reduction, while 25% report a 50-75% reduction in pain.
- A smaller group (16%) has observed more than 75% reduction in VAS scores, indicating significant pain relief. This reflects the variability in pain management outcomes with this combination therapy.

13. In your clinical practice, what kind of medical history do you consider to have caution while prescribing for your patients who are on Pregabalin & Etoricoxib combination therapy?

A. Peptic ulcer disease

B. Asthma

C. Hypercholesterolemia

D. Migraine



- In clinical practice, the most commonly considered medical history that warrants caution when prescribing Pregabalin and Etoricoxib combination therapy is peptic ulcer disease (49%), due to gastrointestinal risks. 18% of clinicians take asthma into account, while 25% consider hypercholesterolemia due to potential cardiovascular effects.
- A smaller portion (8%) views migraine as relevant for careful consideration when prescribing this combination therapy.

14. **According to your practice, how does the Pregabalin and Etoricoxib combination affect the need for non-pharmacological pain management strategies?**

A. Significantly reduces the need

B. Moderately reduces the need

C. Does not reduce the need



- In clinical practice, most clinicians (59%) believe that Pregabalin and Etoricoxib combination therapy significantly reduces the need for non-pharmacological pain management strategies, such as physical therapy or lifestyle changes.
- 25% feel that it moderately reduces the need for these approaches, while 16% believe that it does not reduce the need for non-pharmacological strategies, indicating that the therapy complements, but doesn't fully replace, other treatment methods.

15. According to your opinion, do you consider pregabalin as more effective option for management of neuropathic pain compared to Gabapentin?

A. Yes

B. No

C. Consideration depends upon patient's history



- Yes (41%): Clinicians who select this option believe that Pregabalin is a more effective option for the management of neuropathic pain compared to Gabapentin.
- No (43%): This group does not consider Pregabalin to be more effective than Gabapentin, suggesting that both medications have similar efficacy.
- Consideration depends upon patient's history (16%): A smaller portion believes that the effectiveness of Pregabalin compared to Gabapentin depends on the individual patient's medical history.

16. **In your clinical practice, what percentage of your patients on the Pregabalin and Etoricoxib combination report significant pain relief?**

A. >75%

B. 50-75%

C. 25-50%

D. <25%



- In clinical practice, opinions on the effectiveness of Pregabalin and Etoricoxib combination therapy in providing significant pain relief vary. 33% of clinicians report that more than 75% of their patients experience significant pain relief.
- 26% believe 50-75% of patients achieve meaningful relief, while 25% report 25-50% of patients benefit. 16% state that less than 25% of their patients experience significant pain relief with this combination therapy.
- This reflects the diverse outcomes observed in clinical settings.

17. **According to your opinion, how does the Pregabalin and Etoricoxib combination impact the duration of chronic pain episodes?**

A. Significantly shortens duration

B. Moderately shortens duration

C. No effect on duration



- Most clinicians (51%) believe that Pregabalin and Etoricoxib combination therapy significantly shortens the duration of chronic pain episodes.
- 33% feel it moderately reduces the length of these episodes, while 16% report that the combination therapy has no effect on the duration of chronic pain. This reflects differing clinical experiences regarding the impact of this treatment on pain episode duration.

18. In your clinical practice, how would you rate the safety profile of pregabalin in long-term use for DPNP?

A. Very safe with minimal side effects

B. Moderately safe with some concerning side effects

C. Unsafe and should be used with caution



- In clinical practice, opinions on the safety profile of Pregabalin during long-term use for diabetic peripheral neuropathic pain (DPNP) vary.
- 49% of clinicians consider Pregabalin to be very safe with minimal side effects, while 34% believe it is moderately safe but with some concerning side effects. 17% view Pregabalin as unsafe for long-term use, suggesting it should be used with caution.
- This reflects the diverse perspectives regarding its safety in long-term management of DPNP.

19. **According to your opinion, how likely would you recommend using Pregabalin and Etoricoxib combination to your colleagues for their patients?**

A. Very likely

B. Likely

C. Somewhat likely

D. Unlikely



- In clinical practice, opinions vary on how likely clinicians are to recommend Pregabalin and Etoricoxib combination therapy to their colleagues.
- 41% are very likely to recommend it, while 25% are likely to do so, 18% are somewhat likely, and 16% are unlikely to recommend the combination therapy.
- This reflects differing levels of confidence and experience with the therapy among healthcare professionals.

20. In your clinical practice, how would you rate the impact of the Pregabalin and Etoricoxib combination on patients' ability to perform daily activities?

A. Significant improvement

B. Moderate improvement

C. No improvement



- In clinical practice, the impact of Pregabalin and Etoricoxib combination therapy on patients' ability to perform daily activities is seen differently by clinicians.
- 51% report significant improvement, while 33% observe moderate improvement. 16%, however, feel that the combination therapy has no impact on patients' daily functioning.
- This reflects the diverse experiences with how the therapy affects patients' quality of life.

SUMMARY

This study provides valuable insights into clinicians' practices, experiences, and opinions on the use of Pregabalin and Etoricoxib combination therapy for neuropathic pain.

- **Prescribing Frequency:** Pregabalin with COX inhibitors is frequently prescribed by 51% of clinicians, with another 33% occasionally using this combination.
- **Primary Indications:** Common uses include chronic low back pain or sciatica (33%), post-herpetic neuralgia (26%), diabetic peripheral neuropathy (25%), and trigeminal neuralgia (8%).
- **Treatment Duration:** 49% of clinicians prescribe the combination for less than six months, while 25% consider 6–12 months appropriate. About 26% recommend it for more than a year in chronic cases.
- **Dosing Preferences:** The most recommended starting dose is Pregabalin 75 mg/Etoricoxib 60 mg (49%). A once-daily dosing regimen is preferred by 59% of clinicians for convenience and sustained effectiveness.
- **Efficacy:**
    - 51% of clinicians believe the combination significantly shortens chronic pain episode durations, with 33% reporting moderate reductions.
    - Pain relief outcomes vary, with 25% observing a 50-75% reduction in pain scores and 16% reporting >75% reductions.
- **Patient Benefits:** Young adults are seen as the primary beneficiaries (41%), followed by pediatric (34%) and elderly patients (25%).

- **Safety and Adverse Effects:**
    - Weight gain (51%), hypotension (25%), photosensitivity (16%), and respiratory depression (8%) are the most commonly reported side effects.
    - Pregabalin is considered very safe for long-term use by 49% of clinicians, while 34% believe it is moderately safe.
- **Combination vs. Monotherapy:** 59% of clinicians believe the combination therapy is superior to Pregabalin monotherapy, though 66% have discontinued its use in some cases due to adverse effects.
- **Comparison with Gabapentin:** 41% of clinicians find Pregabalin more effective than Gabapentin, while 43% consider both equally effective.
- **Response to Ineffectiveness:**
    - 49% of clinicians switch to alternative therapies if the combination is ineffective.
    - 26% consider increasing the Pregabalin dose, while 25% add another drug to enhance pain relief.
- **Impact on Quality of Life:** 51% of clinicians report significant improvements in patients' daily functioning, while 33% observe moderate improvements.
- **Clinician Recommendations:** 41% are very likely to recommend the therapy to colleagues, with 25% likely and 18% somewhat likely to do so.

This summary highlights the diverse practices and experiences among clinicians, showcasing the combination therapy's effectiveness, safety, and challenges in managing neuropathic pain.

DISCUSSION

Based on the survey data, the findings highlight the significance of the Pregabalin and Etoricoxib combination in managing neuropathic pain, underscoring its clinical versatility and therapeutic benefits. This combination therapy is particularly valued for its ability to address complex pain conditions such as chronic low back pain, diabetic peripheral neuropathy, and neuralgias. Its broad applicability across diverse patient populations reflects its integral role in clinical practice.

One of the notable advantages of this combination is its perceived effectiveness in providing significant pain relief. Many clinicians report meaningful improvements in patient outcomes, with some observing reductions in pain intensity by up to 75%. This aligns with its dual mechanism of action, combining the analgesic effects of Pregabalin with the anti-inflammatory properties of Etoricoxib, making it a powerful option for multimodal pain management.

The survey results also shed light on clinicians' dosing preferences and treatment duration. The majority favor initiating therapy with lower doses (Pregabalin 75 mg/Etoricoxib 60 mg) to ensure tolerability while tailoring treatment to individual patient needs. Shorter treatment durations are commonly recommended, though extended therapy is considered for chronic or severe conditions requiring long-term management. This cautious yet adaptable approach highlights the importance of balancing efficacy with patient safety.

In terms of safety, while the combination is generally well-tolerated, weight gain and hypotension are the most commonly reported adverse effects, with a smaller proportion noting concerns such as photosensitivity or respiratory depression. Despite these side effects, most clinicians consider the combination safe for long-term use, emphasizing the importance of patient-specific monitoring and management strategies to mitigate risks.

The variation in clinicians' perspectives on the onset of action and pain relief outcomes reflects the diverse responses observed in neuropathic pain management. Some report rapid onset of relief within 30 minutes to 2 hours, while others observe more gradual improvements. This underscores the need for personalized treatment plans, as patient responses can vary widely based on the underlying condition and individual factors.

Patient-specific considerations also play a crucial role in therapy decisions. Clinicians identify medical histories, such as peptic ulcer disease or cardiovascular risks, as factors requiring caution. These findings emphasize the importance of a thorough patient evaluation before initiating combination therapy to minimize potential complications.

Interestingly, clinicians hold differing views on the relative effectiveness of Pregabalin compared to Gabapentin. While some find Pregabalin more effective, others consider both equally beneficial, indicating that the choice of therapy often depends on the clinical context and patient characteristics. Similarly, while the combination is preferred over monotherapy for its added anti-inflammatory benefits, it complements rather than replaces non-pharmacological strategies, highlighting the importance of a comprehensive pain management approach.

In conclusion, the Pregabalin and Etoricoxib combination emerges as a valuable tool in neuropathic pain management. Its efficacy, safety profile, and adaptability to various clinical scenarios make it a preferred choice among clinicians. However, the findings also highlight the importance of individualized therapy, vigilant monitoring of adverse effects, and further research to optimize treatment strategies and address the diverse challenges associated with neuropathic pain.

CLINICAL RECOMMENDATIONS

1. **Tailored Dosing:** Start with lower doses (Pregabalin 75 mg/Etoricoxib 60 mg) to assess tolerance, gradually increasing as needed. For severe cases, higher doses (Pregabalin 150 mg/Etoricoxib 90 mg) can be introduced carefully, optimizing efficacy and patient comfort.
2. **Side Effect Management:** Monitor for common side effects like weight gain and hypotension. Adjust doses, provide supportive therapy, and educate patients about managing mild side effects, ensuring better adherence and reducing discontinuation risk.
3. **Patient Education:** Inform patients about the expected symptom relief timeline and potential side effects. Emphasize the importance of adherence to achieve optimal results and encourage open communication about concerns.
4. **Early Monitoring:** Conduct regular follow-ups within the first 1-2 hours to assess symptom relief and tolerability. Early adjustments based on patient response help maintain progress and build patient confidence in the treatment.

These strategies ensure Pregabalin and Etoricoxib combination therapy is used effectively, improving outcomes and enhancing patient experience.

CONSULTANT OPINION

Expert consultants generally view the combination therapy of Pregabalin and Etoricoxib as a promising option for managing neuropathic pain. They acknowledge its effectiveness in alleviating pain, particularly for conditions like chronic low back pain, diabetic peripheral neuropathy, and sciatica. Consultants

highlight the importance of careful dose adjustment, starting at lower doses to assess patient tolerance and gradually increasing based on symptom severity.

However, they express concerns regarding potential side effects, such as weight gain, hypotension, and dizziness, which need to be closely monitored during treatment. They recommend ongoing assessment to ensure patient safety and effectiveness, advocating for regular follow-ups and timely interventions if side effects occur.

Consultants also call for further research into the long-term safety and efficacy of this combination therapy, which would help refine clinical guidelines and improve its sustainability as a treatment option. By maintaining close vigilance on patient responses, clinicians can ensure that Pregabalin and Etoricoxib remain effective and safe choices for managing neuropathic pain.

MARKET OPPORTUNITIES

The combination therapy of Pregabalin and Etoricoxib presents several strategic opportunities in the pharmaceutical market:

1. **Addressing Unmet Medical Needs**: Chronic low back pain (CLBP) often involves both nociceptive and neuropathic components, necessitating multifaceted treatment approaches. The fixed-dose combination (FDC) of low-dose Pregabalin prolonged release (75 mg) and Etoricoxib (60 mg) effectively targets these dual pain mechanisms, offering a comprehensive solution for patients with CLBP.
2. **Enhanced Clinical Adoption**: Clinical studies have demonstrated that this FDC provides statistically and clinically significant improvements in pain reduction, functionality, and quality of life for patients with CLBP. Such

compelling evidence supports its integration into clinical practice, potentially increasing its adoption among healthcare providers.

3. **Rapid Onset of Action**: The FDC formulation is designed to deliver immediate relief through the rapid release of Etoricoxib, while the prolonged-release Pregabalin component ensures sustained analgesic effects. This dual-action mechanism offers patients prompt and lasting pain management, enhancing treatment satisfaction.

4. **Patient-Centric Benefits**: By addressing both nociceptive and neuropathic pain components at low doses, the FDC minimizes the risk of adverse effects commonly associated with higher doses of monotherapy. This approach reduces pill burden and improves patient compliance, leading to better overall treatment outcomes.

5. **Targeted Market Segments**: The FDC is particularly beneficial for patients with CLBP who have not achieved adequate pain relief with monotherapy. Its ability to address multiple pain pathways positions it as a preferred option in this segment, potentially capturing a significant share of the CLBP treatment market.

6. **Educational Initiatives for Clinicians**: To maximize the therapeutic benefits of this FDC, it is essential to educate healthcare providers on its dual-action mechanism, dosing strategies, and patient selection criteria. Implementing educational programs can enhance prescribing practices and ensure optimal patient outcomes.

7. **Differentiation from Competitors**: Unlike traditional monotherapies, the Pregabalin and Etoricoxib FDC offers a unique combination that addresses both pain components effectively. Highlighting this distinctive feature can differentiate it from other pain management options in the market,

appealing to both clinicians and patients seeking comprehensive pain relief solutions.

8. **Potential for Broader Applications**: While primarily indicated for CLBP, the FDC's mechanism of action may be beneficial in other pain conditions involving both nociceptive and neuropathic components. Exploring its efficacy in conditions such as fibromyalgia or diabetic peripheral neuropathy could open new market opportunities and expand its therapeutic reach

MARKET POSITIONING

The fixed-dose combination (FDC) of low-dose pregabalin prolonged release (75 mg) and etoricoxib (60 mg) has demonstrated significant efficacy in managing chronic low back pain (CLBP) by addressing both nociceptive and neuropathic components of pain.

1. **Targeted Marketing to Healthcare Professionals:**
    - Highlight the FDC's dual-action mechanism, emphasizing its ability to address both nociceptive and neuropathic pain components.
    - Promote the FDC as a preferred choice for patients requiring rapid and sustained pain relief, especially those with complex pain profiles.
2. **Educational Initiatives:**
    - Develop and disseminate comprehensive educational materials, including webinars and continuing medical education (CME) modules, to enhance clinicians' understanding of the FDC's benefits, dosing guidelines, and patient outcomes.

- Organize workshops and seminars to facilitate direct engagement between healthcare providers and experts, fostering a deeper appreciation of the FDC's clinical advantages.

3. **Patient-Centric Approaches:**

    - Position the FDC as a patient-friendly treatment option, emphasizing its effectiveness and minimal side effects.
    - Utilize patient success stories and testimonials to build trust and encourage adoption among new users.

4. **Competitive Analysis:**

    - Regularly assess the competitive landscape to identify emerging treatments and adjust marketing strategies accordingly.
    - Highlight the FDC's unique combination of pregabalin and etoricoxib, differentiating it from other analgesic options available in the market.

By implementing these strategies, the FDC of pregabalin and etoricoxib can strengthen its position in the market, offering a comprehensive solution for patients with CLBP and enhancing overall treatment outcomes.

REFERENCES

1. Van Hecke O, Austin SK, Khan RA, *et al*. Neuropathic pain: a review of its epidemiology and associated factors in population-based studies. Pain. 2014;155(4):654-62.
2. Gilron I, Bailey JM, Tu D, *et al.* Combination pharmacotherapy for the treatment of chronic pain: from bench to bedside. Pain. 2009;142(3):213-9.
3. Skljarevski V, Friedman BW, O'Connor AB, *et al.* Pregabalin and etoricoxib in combination for the treatment of chronic low back pain: a randomized controlled trial. Pain. 2011;152(10):2258-68.
4. Dworkin RH, O'Connor AB, Backonja M, *et al.* Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-51.
5. Rowbotham M, Wang Y, Fields H*, et al.* Pregabalin for the treatment of painful diabetic peripheral neuropathy: a randomized, double-blind, multicenter trial. Neurology. 2004;62(1):132-8.
6. Singh JA, Christensen R, Wells GA, *et al.* Efficacy and safety of etoricoxib in osteoarthritis and rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Ann Rheum Dis. 2008;67(8):1299-307.
7. Derry S, Schumann R, Moore RA, *et al*. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.

For the use or a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

Office No: 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali (East), Mumbai - 400101. M:9322615653. W:www.wmefi.co.in